Innovation in
Antibody
Development.

Vybion is a leading developer of human monoclonal antibody drugs for unmet needs with large markets. Our proprietary technologies bring improved economy and decrease time to market. Vybion’s first drug, CoMab, is for the acute care market and the ProCode Platform is driving human Mab drug development in several focused therapeutic areas.

LATEST NEWS:
Jun 10, 2009
Ithaca, NY: Vybion has received a $1.3M subcontract on at $7.1M NIH Cooperative Agreement to develop diagnostics for Lassa Virus, a deadly hemorrhagic virus endemic in West Africa. More»
Oct 1, 2008
Ithaca, NY: Vybion announces the addition of Drs. Matthew DeLisa, William Ball and Andrew Norman to its Scientific Advisory Board. More»
Jul 10, 2008
Denver, CO: Corgenix Medical Corporation expands effort for developing test kits for viral hemorrhagic fever detection. More»
April 11, 2007
Ithaca, NY: Vybion, Inc. was awarded a contract by P2D in Cincinnati as part of collaboration on an SBIR Phase II grant. Vybion is developing a humanized version of the monoclonal antibody genes. More»
January 22, 2007
Ithaca, NY: Vybion has exclusively licensed a drug development platform from Cornell University. More»
January 8, 2007
San Diego, CA: Vybion CEO, Lee Henderson, Ph.D., made a poster presentation at the annual PepTalk Conference in San Diego on the ProCode Technology. More»

  • Human monoclonal antibody selection
  • Affinity maturation simultaneously with selection
  • Protein solubility optimization
  • Molecule format engineering
  • Complete development and process package